The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.
Gainers in the index outpaced the decliners 19 to nine, and the index outpaced the Dow Jones Industrial Average and Nasdaq Biotechnology Index but lagged the Nasdaq.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
The company reported increase US and international revenues and test volumes, driven by increased adoption and expanding public and private payor coverage.
After the merger closes, the combined company will be split into four units focused on Cologuard, Oncotype Dx, international business, and pipeline efforts.
